Details for New Drug Application (NDA): 089395
✉ Email this page to a colleague
NDA 089395 describes VINBLASTINE SULFATE, which is a drug marketed by Abraxis Pharm, Fresenius Kabi Usa, Hikma, and Hospira, and is included in four NDAs. It is available from one supplier. Additional details are available on the VINBLASTINE SULFATE profile page.
The generic ingredient in VINBLASTINE SULFATE is vinblastine sulfate. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vinblastine sulfate profile page.
The generic ingredient in VINBLASTINE SULFATE is vinblastine sulfate. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vinblastine sulfate profile page.
Summary for 089395
| Tradename: | VINBLASTINE SULFATE |
| Applicant: | Hikma |
| Ingredient: | vinblastine sulfate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 089395
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 10MG/VIAL | ||||
| Approval Date: | Apr 9, 1987 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
